Cancer is insidious. Throughout tumor progression, the disease hijacks otherwise healthy biological processes - like the body's immune response - to grow and spread. When tumors elevate levels of an ...

EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") an innovative biotechnology company focused on developing transformative treatments for chronic inflammatory conditions and debilitating retinal ...

Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) ...

Researchers have discovered a new potential drug target for the lethal wasting disease known as cancer cachexia. Their findings illustrate that even small groups of neurons in the brain can have an ...

Cachexia is a paraneoplastic syndrome of unintentional adipose and muscle tissue wasting with severe impacts to functionality and quality of life. Although health inequities across minority and ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cancer cachexia therapeutics market and it is poised to grow by USD 568.85 million during 2019-2023, progressing at a CAGR of 6% during the ...

Impact of the change in service name from “palliative” to “supportive” care on patient referral at a comprehensive cancer center. Background: Cancer-induced cachexia is the most common paraneoplastic ...